State of the art and future perspectives in cytostatic treatment of esophageal cancer

European Surgery - Acta Chirurgica Austriaca

Volumn 39, Issue 3, 2007, Pages 151-157

  Hejna, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Esophageal cancer; Palliative chemotherapy; Review

Indexed keywords

ALPHA2A INTERFERON; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DICHLOROMETHOTREXATE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITHRAMYCIN; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRIMETREXATE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BARIUM ENEMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOSTASIS; DOSE RESPONSE; DRUG EFFICACY; ELECTROCORTICOGRAPHY; ENDOSCOPY; ESOPHAGUS CANCER; HUMAN; MEDLINE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34547129566     PISSN: 16821769     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10353-007-0331-7     Document Type: Article

References (57)

1. Daly JM, Karnell LH, Menck HR (1996) National cancer data base report on esophageal carcinoma. Cancer 78: 1820-1828
2. Parkin D, Pisani P, Ferley J (1999) Global cancer statistics. Ca Cancer J Clin 49: 33-64
3. Clinical Screening Group (1970) Study of the clinical efficiency of bleomycin in human cancer. Br Med J 2: 643-646
4. Yagoeda A, Mukherji B, Young C, Etcubanas E, Lamonte C, Smith JR, Tan CT, Krakoff IH (1972) Bleomycin, an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 77: 861-870
5. Stephens F (1973) Bleomycin: a new approach in cancer chemotherapy. Med J Aust 1: 1277-1279
6. Ravry M, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RS (1973) Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin (NSC 1125066). Cancer Chemother Rep 57: 493-497
7. Tancini G, Bejetta E, Bonnadonna G (1973) Therapy with bleomycin alone or in combination with methotrexate in epidermoid carcinoma of the esophagus. Tumori 60: 65-71
8. Manell A, Becker PJ, Melissas J, Diamantes T (1986) Intubation versus dilatation plus bleomycin in the treatment of advanced oesophageal cancer: the results of a prospective randomized trial. S Afr J Surg 24: 15-19
9. Davis S, Shanmugathasa M, Kessler W (1980) Cis-dichlorodiamminc platinum(11) in the treatment of esophageal carcinoma. Cancer Treat Rep 64: 709-712
10. Ravry MJ, Moore MR, Omura GA, Esseese I, Bartolucci A (1985) Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: A Southeastern Cancer Study Group trial. Cancer Treat Rep 69: 1457-1485
11. Panettiere F, Leichman L, Tilchen E, Chen TT (1984) Chemotherapy for advanced epidermoid carcinoma of the esophagus with single agent cisplatin: final report on Southwest Oncology Group Study. Cancer Treat Rep 68: 1023-1026
12. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220
13. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091
14. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB 3rd (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87-93
15. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 20(1): 95-99
16. Kelsen DP, Bains MS, Cvitkovic E, Golbey R (1979) Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63: 2019-2021
17. Bedikian AY, Valdivieso M, Bodey GP, Freireich EJ (1979) Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother Pharmacol 2: 263-266
18. Conroy TC, Etienne PL, Adenis A, Pazdur R, Lynch PM, Kelsen DP (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14: 164-170
19. Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H (1992) Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol 29: 321-322
20. Coonley CJ, Baines M, Heelan R, Dukeman M, Kelsen DP (1983) Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67: 397-398
21. Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken EO, Zeitz M, Scherubl H (2003) A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 18(4): 330-334
22. Lokich JJ, Shea M, Chaffey J (1980) Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 60: 275-279
23. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG (1980) Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46: 2149-2153
24. Bajorin D, Kelsen D, Heelan R (1986) Phase II trials of dischloromethotrexate in epidermoid carcinoma of the esophagus. Cancer Treat Rep 70: 1245-1246
25. Alberts AS, Falkson G, Badata M, Terblanche AP, Schmid EU (1988) Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 6: 319-321
26. Nanus DM, Kelsen DP, Lipperman R, Eisenberger M (1988) Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Invest New Drugs 6: 239-241
27. Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D (2000) Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 11(9): 1161-1164
28. Levard H, Pouliquen X, Hay JM, Fingerhut A, Langlois-Zantain O, Huguier M, Lozach P, Testart J (1998) 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicenter randomized controlled trial. The French Associations for Surgical Research. Eur J Surg 164(11): 849-857
29. Nicolaou N, Conlan AA, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA (1982) Cyclophosphamide, doxorubicin and Celestin intubation for inoperable oesophageal carcinoma. S Afr Med J 61: 428-431
30. Bleiberg H, Jacob JH, Bedenne L, Paillot B, DeBesi P, Lacave A (1997) Randomized phase II trial of 5-fluorouracil (5-FU) and cisplatin (DDP) versus DDP alone in advanced esophageal cancer. Eur J Cancer 33(8): 1216-1220
31. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31(9): 419-423
32. Caroli-Bosc FX, Van Laethem JL, Michel P, Gay F, Hendlisz A, Forget F, Bleiberg H (2001) A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) + leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Eur J Cancer 37(15): 1828-1832
33. Lovett D, Kelsen D, Eisenberger M, Houston C (1991) A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus. Cancer 67: 354-358
34. Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J, European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group (2002) European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 13(5): 721-729
35. Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ (2004) Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 15(2): 230-235
36. Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL, Southwest Oncology Group Study (2004) Southwest Oncology Group Study. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: A Southwest Oncology Group Study. Invest New Drugs 22(1): 91-97
37. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickishe T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced oesophagogastric cancer. J Clin Oncol 20(8): 1996-2004
38. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267
39. Polee MB, Kok TC, Siersema PD, Tilanus HW, Splinter TA, Stoter G, Van der Gaast A (2001) Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 12(6): 513-517
40. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16(8): 1320-1325
41. El-Rayes BF, Shields A, Zalupski M, Pazdur R, Lynch PM, Kelsen DP (2004) A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 15(6): 960-965
42. Kelsen D, Ginsberg R, Bains M, Cooper J, Arquette M, Forastiere AA, Ilson D (1997) A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol 24(S19): 77-81
43. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP (2000) A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6(5): 316-323
44. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A (2002) Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 86(5): 669-673
45. Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ (2005) Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 20(4): 618-623
46. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834
47. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92(12): 2129-2133
48. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, Heelan R, Lightdale C (1992) Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 10: 269-274
49. Wadler S, Fell S, Haynes H, Katz HJ, Rozenblit A, Kaleya R, Wiernik PH (1993) Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 71: 1726-1730
50. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, Kelsen DP (1995) A phase II trial of interferon alfa-2a, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 74: 2197-2202
51. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M (2002) A multicenter, randomized phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 13(10): 1568-1575
52. Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP (2005) A phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma. Oncology 69(2): 130-134
53. Ilson DH, Saltz L, Enzinger P, Pazdur R, Lynch PM, Kelsen DP (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17(10): 3270-3275
54. Meluch AA, Hainsworth JD, Gray JR, Thomas M, Whitworth PL, Davis JL, Greco FA (1999) Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 5: 84-91
55. Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayodee K, Forastiere AA (2000) Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18: 868-876
56. Mauer AM, Haraf DC, Ferguson MK, von Delius S, Hennig M, Bredenkamp R, Peschel C (2000) Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia. J Am Clin Oncol 19: 954-960
57. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004